louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00505102: Safe Renal Function In Long Term Heart Transplanted Patients
Official title: Efficacy and Safety of Everolimus to SAve REnal Function (SAREFU) in Long Term Heart Transplanted Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Kidney Diseases
Heart Transplantation
Keywords: Kidney Diseases
Heart Transplantation
Everolimus
Cyclosporine Toxicity
Lead sponsor: A.O. Ospedale Papa Giovanni XXIII
Sponsor class: OTHER
Collaborators: name: Mario Negri Institute for Pharmacological Research
First posted: 2007-07-20
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to verify whether the reduction of cyclosporine dosages associated with Everolimus administration may improve renal function as compared to patients maintained on standard immunosuppressive therapy


Eligibility criteria: Inclusion Criteria:

* Heart Transplant patients with more than 1 year of follow-up
* Creatinine lower than 3.5 mg/dl
* GFR Higher than 20 ml/min (calculated with Cockcroft-Gault formula)
* Cyclosporine in maintenance immunosuppressive therapy
* Patient must be able to sign an approve informed consent
* Prior History of acute rejection within the last 3 months
* Females of childbearing age may be included if pregnancy is excluded and acceptable contraception measures are used

Exclusion Criteria:

* Patients who are recipients of multiple organ transplants
* Prior or current use of sirolimus or everolimus
* History of acute rejection within the last 6 months
* Coronary Artery Bypass Surgery or other cardiac surgery in the past 3 months
* Patient not able to attend all follow-up evaluations

Primary outcomes:
measure: Renal function Evaluated measuring Creatinine, Creatinine Clearance (MDRD and Cockcroft-Gault) and Urinary excretion of Protein, albumin and alpha-1-microglobulin
timeFrame: 2 years
Secondary outcomes:
measure: All cause mortality, infections, incidence of acute myocardial rejection, Heart Failure, Chronic Rejection, Mace
timeFrame: 2 years
Other outcomes:
Locations:
city: Bergamo
country: Italy
facility: Heart Transplant Center Ospedali Riuniti
city: Bergamo
country: Italy
facility: Heart Transplantad Center OspedaliRiuniti Bergamo
Study officials:
affiliation: Heart Transplant Center Ospedali Riuniti Bergamo
name: Roberto Fiocchi, MD PhD
role: STUDY_DIRECTOR
References:
citation: Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003 Sep 4;349(10):931-40. doi: 10.1056/NEJMoa021744.
citation: Rothenburger M, Teerling E, Bruch C, Lehmkuhl H, Suwelack B, Bara C, Wichter T, Hinder F, Schmid C, Stypmann J. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up. J Heart Lung Transplant. 2007 Mar;26(3):250-7. doi: 10.1016/j.healun.2007.01.017.
Clinical trial NCT01417702: Endoscopy for Assessment of Mucosal Healing in IBD
Official title: Advanced Endoscopic Imaging Using HD+ Endoscopy and i-Scan for Assessment of Mucosal Healing in IBD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Crohn´s Disease
Ulcerative Colitis
Lead sponsor: University of Erlangen-Nürnberg Medical School
Sponsor class: OTHER
First posted: 2011-08-16
Enrollment: 232
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Crohn´s disease and ulcerative colitis were prospectively included.

Brief summary: Inflammatory bowel disease (IBD) encompasses two major forms of chronic intestinal disorders, Crohn's disease and ulcerative colitis (UC). Diagnosis is based on several macroscopic and histologic features including patterns of inflammation, crypt abscesses and granulomas. i-Scan use an endoscopic image from the video processor and reconstruct virtual images in real time, resulting in an improved contrast of the capillary patterns and enhancement of the mucosal surface (so called virtual chromoendoscopy).

The main objective of this study is to determine endoscopic features of mucosal healing in patients with IBD and to compare these features to clinical and histological data in order to establish a new endoscopic classification of mucosal healing and to evaluate mucosal healing as a parameter of remission and relapse.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Age 18-85 years
* Ability of subjects to understand character and individual consequences of clinical trial
* Subjects undergoing colonoscopy

Exclusion Criteria:

* Inability to provide written informed consent
* Severe Coagulopathy (Prothrombin time \< 50% of control, Partial thromboplastin time \> 50 s)
* Pregnancy or breast feeding
* Active gastrointestinal bleeding
* Residing in institutions (e.g. prison)
* Proctocolectomy

Primary outcomes:
measure: Mucosal healing
timeFrame: up to three years
Secondary outcomes:
measure: Histologic correlation
timeFrame: up to three years
measure: Therapeutic effect
timeFrame: up to three years
Other outcomes:
Locations:
city: Erlangen
country: Germany
facility: University of Erlangen-Nuremberg
Study officials:
affiliation: Department of Medicine I, University of Erlangen-Nuremberg, Germany
name: Helmut Neumann, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Medicine I, University of Erlangen-Nuremberg, Germany
name: Markus F. Neurath, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00200902: Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
Official title: Factors of Treatment Response in Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Depression
Keywords: Major depressive disorder
MDD
Antidepressant
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
Collaborators: name: National Center for Complementary and Integrative Health (NCCIH)
name: Eli Lilly and Company
name: Wyeth is now a wholly owned subsidiary of Pfizer
First posted: 2005-09-20
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.

Detailed description: We are using depression symptom measurements and measurements of brain electrical activity (EEG) to determine what factors may influence whether a patient is likely to show a response to antidepressant medication, placebo, or only clinical visits (without the use of pills) during a treatment trial for depression.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of unipolar major depression

Exclusion Criteria:

* Substance abuse
* Psychotic disorder
* History of severe head trauma

Primary outcomes:
measure: Response as Assessed by Participants' Change in Depression Rating
timeFrame: Baseline, Week 8
measure: Average Change in 3 Weeks of Participant Treatment Expectations
timeFrame: Averaged over 3 time points (Baseline, randomization, and end of lead-in)
measure: Change in Hamilton Depression Assessment Score
timeFrame: Baseline,Week 8
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Laboratory of Brain, Behavior, and Pharmacology
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Andrew F. Leuchter, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Leuchter AF, Hunter AM, Tartter M, Cook IA. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014 Dec;205(6):443-9. doi: 10.1192/bjp.bp.113.140343. Epub 2014 Sep 11.
Clinical trial NCT05672602: Biomarkers of LONG COVID (LONG COVID_LCM)
Official title: Study of Innovative Biomarkers of Systemic Inflammation in LONG COVID Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Long COVID
Lead sponsor: IRCCS Policlinico S. Donato
Sponsor class: OTHER
First posted: 2023-01-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to IRCCS Policlinico San Donato during the acute phase of COVID-19

Brief summary: This observational prospective study is aimed to investigate noncoding RNAs (ncRNAs) such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) as potential peripheral blood biomarkers of severity and poor prognosis in COVID-19 patients. Patients with intermittent or permanent symptoms after COVID-19 at the moment of the recruitment were considered affected by LONG COVID disease. In particular, the aim is to clarify if COVID-19 biomarkers remain deregulated similarly in LONG COVID patients. To this purpose, plasma and peripheral blood mononuclear cells (PBMCs) will be collected and patients will be compared to individuals who have never been affected by COVID-19 or asymptomatic LONG COVID patients.

Detailed description: The investigators will collect plasma and PBMCs from consenting subjects. The investigators will evaluate the expression of miRNAs, lncRNAs and cytokines in patients affected by LONG COVID admitted to IRCCS Policlinico San Donato during the acute phase of COVID-19. In particular, miRNAs will be evaluated in plasma samples while lncRNAs in PBMC samples to clarify their potential as biomarkers.

Eligibility criteria: Inclusion Criteria:

* Previous COVID-19 infection

Exclusion Criteria:

-

Primary outcomes:
measure: LONG COVID biomarkers
timeFrame: Year 1
Secondary outcomes:
Other outcomes:
Locations:
city: San Donato Milanese
country: Italy
facility: Irccs Policlinico San Donato
state: Milan
Study officials:
References:
Clinical trial NCT04649502: Metformin for the Treatment of Hidradenitis Suppurativa (HS)
Official title: Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis Suppurativa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hidradenitis Suppurativa
Lead sponsor: Erasmus Medical Center
Sponsor class: OTHER
First posted: 2020-12-02
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trial
Primary purpose: TREATMENT

Brief summary: A randomized controlled trial investigating the metformin is the treatment for hidradenitis suppurativa. Metformin combined with doxycycline will be compared to the standard treatment of doxycycline monotherapy for HS severity and the effect on the pre-diabetic condition.


Eligibility criteria: Inclusion Criteria:

* Age ≥18 years at baseline
* A diagnosis of HS for at least 1 year prior to baseline
* mild to moderately active disease defined by a HS Physician Global Assessment (HS-PGA) score of 2-3 and the Refined Hurley classification of mild to moderate at baseline
* Indication for systemic therapy; i.e. uncontrolled disease under conventional topical therapy.
* Able and willing to give written informed consent and to comply with the study requirements

Exclusion Criteria:

* Pregnant and lactating women
* Concomitant diabetes mellitus
* Use of antibiotics within 14 days prior to baseline
* Use of immunosuppressing/modulating therapies within 28 days prior to baseline
* A known allergy to metformin or doxycycline or any of the ingredients metformin or doxycycline

Primary outcomes:
measure: IHS4
timeFrame: 24 weeks
Secondary outcomes:
measure: Insulin resistance
timeFrame: 12 and 24 weeks
measure: Lesion Count
timeFrame: 12 and 24 weeks
measure: NRS-Pain
timeFrame: 12 and 24 weeks
measure: Cost-effectiveness
timeFrame: 24 weeks
measure: Bio-markers
timeFrame: 24 weeks
measure: Safety and Tolerability
timeFrame: up to 24 weeks
measure: Metabolic syndrome
timeFrame: 12 and 24 weeks
measure: Pre-diabetic disorder
timeFrame: 12 and 24 weeks
measure: HiSCR
timeFrame: 12 and 24 weeks
measure: HS-PGA
timeFrame: 12 and 24 weeks
measure: Flares
timeFrame: 12 and 24 weeks
measure: DLQI
timeFrame: 12 and 24 weeks
measure: Treatment satisfaction
timeFrame: up to 24 weeks
Other outcomes:
Locations:
city: Rotterdam
country: Netherlands
facility: Erasmus MC
Study officials:
References:
Clinical trial NCT00380302: Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Official title: A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Alzheimer Disease
Keywords: Alzheimer's disease
symptomatic
cognition
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2006-09-25
Enrollment: 162
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill).

Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.


Eligibility criteria: Inclusion Criteria:

* The diagnosis of Alzheimer's disease
* Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI)
* Mild to moderate range of disease; not too severe

Exclusion Criteria:

* Severe or unstable medical diseases
* Neurological disorder other than Alzheimer's disease
* Depression that is not well controlled
* Treatment with memantine
* Inpatient in a total care facility (e.g.: Nursing home)
* Lack of reliable caregiver

Primary outcomes:
measure: Safety and tolerability throughout the study:adverse events collected by spontaneous report
measure: physical examination and neurological assessment
measure: vital sign monitoring, clinical laboratories, and ECGs.
measure: Efficacy variables:measures of change in cognition, global functioning and behavior at week 12.
Secondary outcomes:
measure: Pharmacokinetic parameters will be assessed throughout the 12-week treatment period.
Other outcomes:
Locations:
city: Bridgewater
country: United States
facility: Sanofi-Aventis Administrative Office
state: New Jersey
city: Paris
country: France
facility: Sanofi-Aventis Administrative Office
city: Milano
country: Italy
facility: Sanofi-Aventis Administrative Office
city: Gouda
country: Netherlands
facility: Sanofi-Aventis Administrative Office
city: Bromma
country: Sweden
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: ICD CSD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04185402: Azithromycin Reduction to Reach Elimination of Trachoma
Official title: Azithromycin Reduction to Reach Elimination of Trachoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: Trachoma
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Programme National de Santé Oculaire (PNSO)
name: National Eye Institute (NEI)
First posted: 2019-12-04
Enrollment: 100000
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger. The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution.


Eligibility criteria: Inclusion Criteria:

* Provision of appropriate informed consent
* Stated willingness to comply with all study procedures
* Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial

Exclusion Criteria:

* Does not consent to participation
* Unwilling to comply with all study procedures
* Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial

Primary outcomes:
measure: Ocular chlamydia measured in a population-based sample of 0-9 year-old children
timeFrame: 36 months
Secondary outcomes:
measure: Infectious load of chlamydia among 0-9 year-old children infected with ocular chlamydia
timeFrame: 36 months
measure: Conjunctival inflammation
timeFrame: 36 months
Other outcomes:
Locations:
city: Niamey
country: Niger
facility: Programme National de Santé Oculaire (PNSO)
Study officials:
affiliation: University of California, San Francisco
name: Catherine Oldenburg, ScD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco
name: Tom Lietman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco
name: Elodie Lebas, RN
role: STUDY_DIRECTOR
References:
citation: Amza A, Kadri B, Nassirou B, Arzika AM, Austin A, Nyatigo F, Lebas E, Arnold BF, Lietman TM, Oldenburg CE. Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma. BMC Ophthalmol. 2021 Jan 6;21(1):15. doi: 10.1186/s12886-020-01776-4.
Clinical trial NCT00592202: Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents
Official title: Laparoscopic Adjustable Gastric Banding as a Treatment for Morbid Obesity in Adolescents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Morbid Obesity
Keywords: Morbid obesity
Adolescents
Gastric restrictive procedure
Adjustable gastric band
Treatment
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
First posted: 2008-01-11
Enrollment: 37
Sex: ALL
Minimum age (years): 14
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the LAP-BAND system is safe and effective in morbidly obese adolescents.

Detailed description: The aim of this research is to evaluate the safety and efficacy of the use of the Lap-Band system in the morbidly obese adolescent population in the United States. We also propose to take advantage of the opportunity for liver biopsy and the data collected for the FDA study in adolescents to answer several questions: 1) what is the true incidence of non-alcoholic fatty liver disease (NAFLD) and its variants in morbidly obese adolescents; 2) what is the course of the NAFLD disease in adolescents who have undergone weight loss, including the progression from steatosis to NASH/ fibrosis or the progression of NASH to cirrhosis? 3) What are the factors implicated in this progression and 4) Is there a link between the excess visceral fat, MS and NAFLD as assessed by parallel changes in metabolic syndrome (MS) and NAFLD following weight loss intervention. The LAPBAND may provide obese adolescents with a significantly less morbid and reversible surgical option for weight loss.

Eligibility criteria: Inclusion Criteria:

* Ages 14 through 17
* BMI greater than 40
* BMI 35 to 40 and also having an obesity related comorbidity
* Have a history of working in a multidisciplinary weight loss program utilizing nutritional training, behavior modification, and activity training

Exclusion Criteria:

* Subject history of congenital or acquired anomalies fo the gastrointestinal tract
* Severe cardiopulmonary or other serious organic disease
* Severe coagulopathy
* Hepatic insufficiency or cirrhosis
* History of bariatric gastric or esophageal surgery
* History of intestinal obstruction or adhesive peritonitis
* History of esophageal motility disorders
* Type I diabetes

Primary outcomes:
measure: Weight loss
timeFrame: Every six months
Secondary outcomes:
measure: Resolution of comorbidities
timeFrame: every six months
measure: Assess the status of comorbidities and changes in quality of life scores from baseline.
timeFrame: every six months
Other outcomes:
Locations:
city: Chicago
country: United States
facility: UIMC
state: Illinois
Study officials:
affiliation: Division of Pediatric Surgery, UIC
name: Robert Kanard, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01023802: The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer
Official title: The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer - A Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neoadjuvant Therapy
Chemotherapy
Hormone Replacement Therapy
Breast Cancer
Keywords: neoadjuvant therapy
chemotherapy
hormone therapy
breast cancer
MBI
Molecular Breast Imaging
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2009-12-02
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 20 patients who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.

Brief summary: In patients with breast cancer who undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy molecular breast imaging (MBI) is an accurate test for assessing response rate to neoadjuvant therapy.

Detailed description: The investigators propose to evaluate Molecular Breast Imaging in patients undergoing neoadjuvant therapy for breast cancer with the aims to document that 1) the change in uptake of 99mTc-sestamibi prior to initiation of neoadjuvant therapy, after 3-5 weeks of neoadjuvant therapy and at completion of neoadjuvant therapy prior to breast cancer surgery will be a reflection of the tumor response to neoadjuvant therapy.

2) Tumor response at 3-5 weeks of neoadjuvant therapy is predictive of tumor response at completions of neoadjuvant therapy.

3) Post-neoadjuvant tumor size as determined by MBI corresponds to size found at surgery.

Eligibility criteria: Inclusion Criteria:

* Women with breast cancer scheduled to undergo neoadjuvant chemotherapy therapy or neoadjuvant hormone therapy and who have undergone any breast imaging procedure, and in whom a repeat imaging procedure is planned prior to definite surgery. MRI of the breast for accurate tumor size evaluation is recommended but not necessarily required for study inclusion.
* Are able to return for a 3-5 week follow-up MBI study and for the final MBI study at completion of the neoadjuvant therapy.
* Patient age \> 18

Exclusion Criteria:

* Unable to understand or sign a consent form
* Pregnant or lactating
* Physically unable to sit upright and still for 40 minutes

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic - Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Dietlind L. Wahner-Roedler, M.D.
role: PRINCIPAL_INVESTIGATOR
References: